 |
|
Circulating Erythropoietin Levels and Prognosis in Patients With Congestive Heart Failure
Comparison With Neurohormonal and Inflammatory Markers
Jacob George, MD;
Shuki Patal, MD;
Dov Wexler, MD;
Anastasia Abashidze, BSc;
Haim Shmilovich, MD;
Tomer Barak, MD;
David Sheps, MD;
Gad Keren, MD
Arch Intern Med. 2005;165:1304-1309.
Background Considerable morbidity and mortality are still associated with congestive heart failure (CHF) syndromes, despite improvement in therapy. Activation of neurohormonal, inflammatory, and oxidative mechanisms has been shown to contribute to the significant morbidity and mortality. Erythropoietin (EPO) is a cytokine known to regulate erythroid proliferation, attenuate apoptosis and oxidative stress, and promote angiogenesis. We prospectively evaluated the predictive value of baseline EPO, N-terminal pro–B-type natriuretic peptide, and C-reactive protein levels in patients with clinically controlled chronic CHF.
Methods One hundred eighty-eight outpatients from a CHF clinic had baseline assessment of EPO, N-terminal pro–B-type natriuretic peptide, and C-reactive protein levels and a complete clinical data profile. These patients were followed up for 24 months for any hospitalization due to CHF or mortality.
Results Circulating EPO levels were higher in CHF patients and increased in subjects with higher New York Heart Association scores. Levels of EPO (at a cutoff of 23 mU/mL) and N-terminal pro–B-type natriuretic peptide (cutoff at the median of 1556 pg/mL) were found to be strong predictors of mortality and CHF hospitalization, whereas C-reactive protein levels (cutoff of 10 mg/L) predicted CHF hospitalizations but not mortality. Left ventricular ejection fraction was found to be a predictor of mortality but not of CHF hospitalizations. Serum levels of EPO were significantly correlated with N-terminal pro–B-type natriuretic peptide and C-reactive protein levels but not with left ventricular ejection fraction.
Conclusion If confirmed in large-scale clinical studies, determination of circulating EPO levels may aid in predicting morbidity and mortality in patients with clinically controlled congestive CHF.
Author Affiliations: Department of Cardiology, Tel Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial
McMurray et al.
Eur J Heart Fail 2009;11:795-801.
ABSTRACT
| FULL TEXT
Anemia: the point of convergence or divergence for kidney disease and heart failure?
Kazory and Ross
J Am Coll Cardiol 2009;53:639-647.
ABSTRACT
| FULL TEXT
Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients
van der Meer et al.
Eur Heart J 2008;29:1510-1515.
ABSTRACT
| FULL TEXT
Erythropoietin and outcome prediction in patients with heart failure: the plot thickens...
George
Eur Heart J 2008;29:1481-1482.
FULL TEXT
Anemia and Heart Failure: A New Pathway?
Francis and Kanderian
J Am Coll Cardiol 2007;50:1666-1667.
FULL TEXT
Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well
Westenbrink et al.
Eur Heart J 2007;28:166-171.
ABSTRACT
| FULL TEXT
The Year in Heart Failure
Tang and Francis
J Am Coll Cardiol 2005;46:2125-2133.
FULL TEXT
Anemia and Chronic Heart Failure: Are We Asking the Right Questions?
Clark and Cleland
Circulation 2005;112:1681-1683.
FULL TEXT
|
